Key result
Post-TAVI infective endocarditis occurs in ~0.5% at 1 year, linked to intubation and self-expandable valves.
Why the study?
The incidence, predictors, clinical characteristics, management, and outcomes of infective endocarditis after TAVI needed to be determined.
What are the incidence, predictors, and clinical outcomes of infective endocarditis following transcatheter aortic valve implantation?
Cohort (n=7,944)
Yes
What are the incidence, predictors, and clinical outcomes of infective endocarditis following transcatheter aortic valve implantation?
Answers are grounded in this paper and cite their sources.
Infective endocarditis after TAVI is a rare (0.50% at 1 year) but highly lethal complication, with increased risk associated with orotracheal intubation and the use of self-expandable valve systems.
BACKGROUND: We aimed to determine the incidence, predictors, clinical characteristics, management, and outcomes of infective endocarditis (IE) after transcatheter aortic valve implantation (TAVI). METHODS AND RESULTS: This multicenter registry included 53 patients (mean age, 79±8 years; men, 57%) who suffered IE after TAVI of 7944 patients after a mean follow-up of 1.1±1.2 years (incidence, 0.67%, 0.50% within the first year after TAVI). Mean time from TAVI was 6 months (interquartile range, 1-14 months). Orotracheal intubation (hazard ratio, 3.87; 95% confidence interval, 1.55-9.64; P=0.004) and the self-expandable CoreValve system (hazard ratio, 3.12; 95% confidence interval, 1.37-7.14; P=0.007) were associated with IE (multivariate analysis including 3067 patients with individual data). The most frequent causal microorganisms were coagulase-negative staphylococci (24%), followed by Staphylococcus aureus (21%) and enterococci (21%). Vegetations were present in 77% of patients (transcatheter valve leaflets, 39%; stent frame, 17%; mitral valve, 21%). At least 1 complication of IE occurred in 87% of patients (heart failure in 68%). However, only 11% of patients underwent valve intervention (valve explantation and valve-in-valve procedure in 4 and 2 patients, respectively). The mortality rate in hospital was 47.2% and increased to 66% at the 1-year follow-up. IE complications such as heart failure (P=0.037) and septic shock (P=0.002) were associated with increased in-hospital mortality. CONCLUSIONS: The incidence of IE at 1 year after TAVI was 0.50%, and the risk increased with the use of orotracheal intubation and a self-expandable valve system. Staphylococci and enterococci were the most common agents. Although most patients presented at least 1 complication of IE, valve intervention was performed in a minority of patients, and nearly half of the patients died during the hospitalization period.
No takes yet. Share an insight, caveat, or question.
Amat‐Santos et al. (2015) conducted a cohort in Infective endocarditis after TAVI (n=7,944). Transcatheter aortic valve implantation (TAVI) was evaluated on Infective endocarditis. The incidence of infective endocarditis at 1 year after TAVI was 0.50%, and the risk increased with the use of orotracheal intubation and a self-expandable valve system.
Synapse has enriched 10 related papers. Consider them for comparative context: